Syed Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Syed Ibrahim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Abdul Basit
Indus Hospital & Health Network (IHHN) Karachi Pakistan
1 shared publicationAbrahim Durrani
Aga Khan University Hospital
1 shared publication- Elizabeth Yu
Department of Orthopaedics, The Ohio State University, Columbus, USA
1 shared publication Muhammad Abdullah Naveed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
1 shared publication- Muhammad Ahmed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
1 shared publication - Muhammad Talal Ibrahim
Division of Spine Surgery, Department of Orthopaedics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
1 shared publication
Latest Publications
- 31 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (6) , 4559-4572
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Background: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patient‐reported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and meta‐analysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods: MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A random‐effects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoB‐2 tool. Results: Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQ‐5D Index score versus placebo (MD: 0.04, p = 0.008), DTR‐QoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQ‐9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), self‐esteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion: Randomised evidence suggests SGLT2 inhibitors enhance EQ‐5D Index score, diabetes‐specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
- 31 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (6) , 4559-4572
Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Quality of Life and Patient‐Reported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Background: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patient‐reported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and meta‐analysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods: MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A random‐effects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoB‐2 tool. Results: Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQ‐5D Index score versus placebo (MD: 0.04, p = 0.008), DTR‐QoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQ‐9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), self‐esteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion: Randomised evidence suggests SGLT2 inhibitors enhance EQ‐5D Index score, diabetes‐specific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
- Top Cited PapersOpen Access
- 3 January 2026
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (5) , 2468-2477
Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis
Study Design: Systematic Review and Meta-Analysis. Objectives: Despite a surge in the use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in spine surgery candidates, evidence on their perioperative use remains unclear. This meta-analysis aimed to synthesize the evidence on the safety and efficacy of GLP-1 RA use in patients undergoing spine surgeries. Methods: A systematic search of PubMed (MEDLINE), Embase, Scopus, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted. Studies that compared spine surgery outcomes in GLP-1 RA users and non-users were included. Two reviewers independently selected articles. (PROSPERO: CRD420251061447). Results: Eleven retrospective studies reporting on 27,143 patients were included. Three studies focused on the cervical spine, 6 on the lumbar spine, and 2 included all spinal fusions. Risk of bias was deemed to be low in all studies. There were no significant differences in the GLP-1 RA users and non-users in pooled estimates for pseudoarthrosis (odds ratio: 1.29 [95% CI: 0.09 - 19.23]), surgical site infections (0.97 [0.74 - 1.27]), pneumonia (1.19 [0.30 - 4.68]), deep vein thrombosis (1.34 [0.86 - 2.08]), acute kidney injury (1.27 [0.93 - 1.74]), readmission rate (1.06 [0.94 - 1.18]), and emergency department visits (0.95 [0.10 - 8.99]). Conclusions: Currently available level 4 evidence suggests that perioperative GLP-1 RA use in spine surgery candidates does not affect the risk of postoperative complications. However, these studies are based on administrative databases and may be confounded by indication. Future studies should include glycemic control and weight loss to better elucidate the impact of GLP-1 RA.
- 3 January 2026
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (5) , 2468-2477
Top Cited PapersOpen AccessGlucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis
Study Design: Systematic Review and Meta-Analysis. Objectives: Despite a surge in the use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in spine surgery candidates, evidence on their perioperative use remains unclear. This meta-analysis aimed to synthesize the evidence on the safety and efficacy of GLP-1 RA use in patients undergoing spine surgeries. Methods: A systematic search of PubMed (MEDLINE), Embase, Scopus, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials (CENTRAL) was conducted. Studies that compared spine surgery outcomes in GLP-1 RA users and non-users were included. Two reviewers independently selected articles. (PROSPERO: CRD420251061447). Results: Eleven retrospective studies reporting on 27,143 patients were included. Three studies focused on the cervical spine, 6 on the lumbar spine, and 2 included all spinal fusions. Risk of bias was deemed to be low in all studies. There were no significant differences in the GLP-1 RA users and non-users in pooled estimates for pseudoarthrosis (odds ratio: 1.29 [95% CI: 0.09 - 19.23]), surgical site infections (0.97 [0.74 - 1.27]), pneumonia (1.19 [0.30 - 4.68]), deep vein thrombosis (1.34 [0.86 - 2.08]), acute kidney injury (1.27 [0.93 - 1.74]), readmission rate (1.06 [0.94 - 1.18]), and emergency department visits (0.95 [0.10 - 8.99]). Conclusions: Currently available level 4 evidence suggests that perioperative GLP-1 RA use in spine surgery candidates does not affect the risk of postoperative complications. However, these studies are based on administrative databases and may be confounded by indication. Future studies should include glycemic control and weight loss to better elucidate the impact of GLP-1 RA.